ReviewThe Journal of infectious diseases2010
End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease.
Review in The Journal of infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 63 citations in OpenAlex.
- A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics.Nature communications · 2020Trial
- Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.The Lancet. Infectious diseases · 2017Trial
- Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study.The Lancet. Respiratory medicine · 2017Trial
- Viral load is strongly associated with length of stay in adults hospitalised with viral acute respiratory illness.The Journal of infection · 2016Trial
- Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.Antimicrobial agents and chemotherapy · 2016Trial
- Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial.BMJ (Clinical research ed.) · 2013Trial
- Comparing antiviral strategies against COVID-19 via multiscale within-host modelling.Royal Society open science · 2021Article
- Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances.Cold Spring Harbor perspectives in medicine · 2021Review
- Respiratory viral sepsis: epidemiology, pathophysiology, diagnosis and treatment.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.Antiviral research · 2019Review
- Influenza virus-related critical illness: prevention, diagnosis, treatment.Critical care (London, England) · 2019Review
- Article
- Oseltamivir Treatment of Influenza in Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
- Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference.Antiviral research · 2018Article
- Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance.PloS one · 2018Article
- The Mechanisms for Within-Host Influenza Virus Control Affect Model-Based Assessment and Prediction of Antiviral Treatment.Viruses · 2017Article
- Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization.Clinical trials (London, England) · 2017Article
- Using Clinical Trial Simulators to Analyse the Sources of Variance in Clinical Trials of Novel Therapies for Acute Viral Infections.PloS one · 2016Article
- How Can Viral Dynamics Models Inform Endpoint Measures in Clinical Trials of Therapies for Acute Viral Infections?PloS one · 2016Article
- A Downward Trend of the Ratio of Influenza RNA Copy Number to Infectious Viral Titer in Hospitalized Influenza A-Infected Patients.Open forum infectious diseases · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 3 countries.
Funding
Abstract
Influenza infection results in substantial morbidity and mortality in hospitalized patients, including those who are immunocompromised or pregnant. Antiviral therapy likely provides considerable benefit to these patients, but few studies have been successfully conducted in these high-risk populations, and no drugs are specifically licensed for treating these subgroups. One of the key challenges facing novel antiviral drug development for influenza is determining the appropriate efficacy end points that would enable rapid regulatory approval for drug use in seriously ill patients, for whom risk-benefit assessments differ from those with uncomplicated illness. All available antiviral drugs currently affect viral replication, and respiratory tract viral titers correlate with both symptoms and measures of host inflammatory responses, including cytokine and chemokine expression that are likely responsible for many of the clinical symptoms. Consequently, we outline the evidence to support the use of primary virological end points in studies of antiviral agents involving patients who are hospitalized with severe influenza or those who are at high risk of severe and life-threatening disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.